À¯·´ÀÇ ¿ÏÁ¦(Fill-Finish) Á¦Á¶ ½ÃÀå : ¿¹Ãø(2030³â)-Áö¿ªº° ºÐ¼®-Á¦Ç°º°, ¸ð´Þ¸®Æ¼º°, ÃÖÁ¾ »ç¿ëÀÚº°
Europe Fill Finish Manufacturing Market Forecast to 2030 - Regional Analysis - by Product, Modality, and End User
»óǰÄÚµå : 1533044
¸®¼­Ä¡»ç : The Insight Partners
¹ßÇàÀÏ : 2024³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 108 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,450 £Ü 4,814,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù.
US $ 4,450 £Ü 6,209,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,450 £Ü 7,604,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

À¯·´ÀÇ ¿ÏÁ¦(Fill-Finish) Á¦Á¶ ½ÃÀåÀº 2022³â¿¡ 24¾ï 7,326¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2030³â¿¡´Â 47¾ï 7,250¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2022³âºÎÅÍ 2030³â±îÁö CAGRÀº 8.6%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

»ý¹°ÇÐÀû Á¦Á¦ ¼ö¿ä Áõ°¡°¡ À¯·´ÀÇ ÃæÀüÁ¦ Á¦Á¶ ½ÃÀåÀ» °ßÀÎ

»ý¹°ÇÐÀû Á¦Á¦´Â ÆÇ¸Å ÀǾàǰÀÇ ´ëºÎºÐÀ» Â÷ÁöÇÏ¸ç °¡Àå ºü¸£°Ô ¼ºÀåÇÏ´Â Á¦¾à »ê¾÷ ºÐ¾ß Áß ÇϳªÀÔ´Ï´Ù. 30³â Àü¿¡ ÀçÁ¶ÇÕ ´Ü¹éÁú ±â¹Ý Ä¡·áÁ¦°¡ Ãâ½ÃµÈ ÀÌ·¡, »ý¹°ÇÐÀû Á¦Á¦ ½ÃÀå Àüü´Â ¿¬·ü 12% ÀÌ»óÀ¸·Î ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÇöÀç 5,000°³°¡ ³Ñ´Â ¹ÙÀÌ¿ÀÀǾàǰ È帰¡ °³¹ß ÁßÀÔ´Ï´Ù. ¹ÙÀÌ¿À ÀǾàǰÀº Å« ÀÌÀÍ·üÀ» °¡Á®¿ÀÁö¸¸, ³ôÀº °³¹ß ºñ¿ë°ú º¹ÀâÇÑ Á¦Á¶ ÇÁ·ÎÅäÄÝÀÌ ÀÌ·¯ÇÑ ¾à¸®ÇÐÀû °³ÀÔÀ» ¼öÇàÇÏ´Â ½ºÆù¼­ÀÇ ÁÖ¿ä ¿ì·Á »çÇ×ÀÔ´Ï´Ù. ±× °á°ú, ÀϺΠ½ÅÈï±â¾÷°ú Á¦¾à ´ë±â¾÷Àº »ç¾÷ ¿î¿µÀÇ ´Ù¾çÇÑ ÇÁ·Î¼¼½º¸¦ À§Å¹ ¼­ºñ½º Á¦°ø¾÷ü¿¡°Ô ¾Æ¿ô¼Ò½ÌÇϱ⠽ÃÀÛÇϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡ Á¦Á¶ ¼öŹ ±â°ü(CMO)°ú °³¹ß Á¦Á¶ ¼öŹ ±â°ü(CDMO)¿¡ ´ëÇÑ ¾÷¹« À§Å¹Àº ¼³ºñ ÅõÀÚÀÇ Çʿ伺À» ÁÙÀ̰í, º¸´Ù Å« »ý»ê ´É·Â¿¡ÀÇ ¾×¼¼½º¸¦ Á¦°øÇØ, Á¦Ç° ½ÃÀå ÅõÀÔ±îÁöÀÇ ½Ã°£À» ´ÜÃàÇϰí Á¦Ç°ÀÇ »ó¾÷È­¿Í °ü·ÃµÈ À§ÇèÀ» ÁÙÀÔ´Ï´Ù.

¿ÏÁ¦ Á¦Á¶´Â Á¦Á¶ °øÁ¤ÀÇ ÃÖÁ¾ ´Ü°èÀ̸ç ÀǾàǰ Á¦Á¶¿¡¼­ °¡Àå Áß¿äÇÑ ´Ü°è Áß ÇϳªÀÔ´Ï´Ù. »ý¹°ÇÐÀû Á¦Á¦´Â Á¦Ç°ÀÇ ¹«°á¼º°ú ¾ÈÀü¼ºÀ» º¸ÀåÇϱâ À§ÇØ Ã¤¿ì±â ¸¶¹«¸® ÀÛ¾÷¿¡ Ưº°ÇÑ ÀýÂ÷¿Í Àåºñ°¡ ÇÊ¿äÇÕ´Ï´Ù. µû¶ó¼­ »ý¹°ÇÐÀû Á¦Á¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó À¯¿¬ÇÑ ¹«±Õ ¿ÏÁ¦ ±â¼ú¿¡ ´ëÇÑ ¿ä±¸°¡ Ä¿Áö°í ÀÖ½À´Ï´Ù. ÀǾàǰ Á¦Á¶¾÷ü´Â ÃֽŠ¿ÏÁ¦ ±â¼ú¿¡ ´ëÇÑ °æÇè°ú Àü¹® Áö½ÄÀ» Ȱ¿ëÇϱâ À§ÇØ À§Å¹ ¼­ºñ½º Á¦°ø ¾÷ü¿Í Çù·ÂÇÕ´Ï´Ù. ÇöÀç ¾à 180°³ ±â¾÷ÀÌ ´Ù¾çÇÑ »ý¹°ÇÐÀû Á¦Á¦ÀÇ ¿ÏÁ¦ Á¦Á¶ ¼­ºñ½º¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¼öŹ Á¦Á¶ ±â¾÷Àº ´Ù¾çÇÑ Áö¿ª¿¡ °ÉÃÄ 350 °³ ÀÌ»óÀÇ ¿ÏÁ¦ °øÀå¿¡ º»»ç¸¦ µÎ°í ÀÖ½À´Ï´Ù.

À¯·´ÀÇ ¿ÏÁ¦ Á¦Á¶ ½ÃÀå °³¿ä

µ¶ÀÏ ½ÃÀå ±â¾÷Àº ½ÃÀå È®´ë¿Í ¼ºÀåÀ» À§ÇØ À¯±âÀû ¹× ¹«±âÀû ¼ºÀå Àü·«À» äÅÃÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2020³â 7¿ù µ¶ÀÏÀÇ ¶óº¥½ººÎ¸£Å©¿¡ º»»ç¸¦ µÎ°í ÀÖ´Â °³¹ß Á¦Á¶ ¼öʱâ°ü(CDMO)ÀÇ Vetter»ç´Â ¿À½ºÆ®¸®¾ÆÀÇ ÀÓ»ó Á¦Á¶ ½Ã¼³ÀÇ ±¸ÀÔ¿¡ ÀÇÇØ ÃæÀü ¹× ¸¶¹«¸® ´É·ÂÀÇ Ãß°¡ ÅõÀÚ¸¦ ½Ç½ÃÇÑ´Ù°í ¹ßÇ¥Çß½À´Ï´Ù.

¸¶Âù°¡Áö·Î ÁöÅ©ÇÁ¸®µå ±×·ìÀº Çõ½ÅÀûÀÎ COVID-19 ¹é½Å Èĺ¸ÀÎ BNT162b2ÀÇ »ó¾÷¿ë·®ÀÇ ´ë±Ô¸ð ÃæÀü ¹× Æ÷Àå°ú °ü·ÃÇÏ¿© µ¶ÀÏÀÇ ¸é¿ª¿ä¹ý ±â¾÷ÀÎ Biopharmaceutical New Technologies¿Í Çù·Â ¹× °ø±Þ °è¾àÀ» ü°áÇß½À´Ï´Ù. ¹ÙÀÌ¿À¿£Å×Å©°¡ ¹Ì±¹ Á¦¾àȸ»ç ÆÄÀÌÀú¿Í °øµ¿À¸·Î °³¹ßÇÑ ÀÌ ¹é½ÅÀº ½ÂÀÎ ÈÄ 2021³â Áß¹Ý ÀÌÈÄ ÁöÅ©Çø´ÀÌ Çϸḥ °øÀå¿¡¼­ ä¿ï ¿¹Á¤ÀÔ´Ï´Ù. ¶ÇÇÑ µ¶ÀÏ¿¡ ÀÖ´Â ¹ÙÀÌ¿À ÀǾàǰ °³¹ß Á¦Á¶ ¼öʱâ°ü(CDMO)ÀÇ ¼±µÎÀÎ ·»½¶·¯ ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö½º»ç¿Í ¹«±ÕÃæÀü ¹× ¸¶¹«¸® ¼­ºñ½ºÀÇ µ¶¸³°è Àü¹®±â¾÷ÀÎ ·»½¶·¯ ÇÊ ¼Ö·ç¼ÇÁî»ç´Â Àü·«Àû Á¦ÈÞ¸¦ ¹ßÇ¥ÇÏ°í ·»½¶·¯ ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö½º»çÀÇ °í°´ÀÇ ¿ä°ÇÀ» ÃæÁ·Çϱâ À§ÇØ »õ·Î¿î ÃÖ÷´ÜÀÇ ÃæÀü ¹× ¸¶¹«¸® ¼³ºñ¿Í ¹ÙÀÌ¿À ÀǾàǰÀÇ ¿ø½ºÅé ¼Ö·ç¼ÇÀ» Á¦°øÇÏ°Ô µÇ¾ú½À´Ï´Ù.

À¯·´ÀÇ ¿ÏÁ¦(Fill-Finish) Á¦Á¶ ½ÃÀåÀÇ ¼öÀÍ ¹× ¿¹Ãø(±Ý¾×)(-2030³â)

À¯·´ÀÇ ¿ÏÁ¦ Á¦Á¶ ½ÃÀåÀÇ ¼¼ºÐÈ­

À¯·´ÀÇ ¿ÏÁ¦ Á¦Á¶ ½ÃÀåÀº Á¦Ç°º°, ¸ð´Þ¸®Æ¼º°, ÃÖÁ¾ »ç¿ëÀÚº°, ±¹°¡º°·Î ¼¼ºÐÈ­µË´Ï´Ù. Á¦Ç°º°·Î, À¯·´ÀÇ ¿ÏÁ¦ Á¦Á¶ ½ÃÀåÀº ¼Ò¸ðǰ°ú ±â±¸·Î À̺е˴ϴÙ. ¼Ò¸ðǰ ºÎ¹®Àº 2022³â¿¡ Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ¶ÇÇÑ ¼Ò¸ðǰÀº ÇÁ¸®Çʵå ÁÖ»ç±â, À¯¸® ¹ÙÀÌ¾Ë ¹× ÇÃ¶ó½ºÆ½ ¹ÙÀ̾Ë, īƮ¸®Áö µîÀ¸·Î ¼¼ºÐÈ­µË´Ï´Ù.

¸ð´Þ¸®Æ¼º°·Î À¯·´ÀÇ Filfinish Á¦Á¶ ½ÃÀåÀº ÀçÁ¶ÇÕ ´Ü¹éÁú, ´ÜÀÏ Å¬·Ð Ç×ü, ¹é½Å, ¼¼Æ÷ ¿ä¹ý ¹× »ý¹°ÇÐÀû ¿ä¹ý, À¯ÀüÀÚ ¿ä¹ý µîÀ¸·Î ºÐ·ùµË´Ï´Ù. 2022³â¿¡´Â ¹é½Å ºÐ¾ß°¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

ÃÖÁ¾ »ç¿ëÀÚº°·Î À¯·´ÀÇ ¿ÏÁ¦ Á¦Á¶ ½ÃÀåÀº ¼öŹ Á¦Á¶ ±â°ü, ¹ÙÀÌ¿À Á¦¾à ȸ»ç µîÀ¸·Î ºÐ·ùµË´Ï´Ù. ¼öŹ Á¦Á¶ ±â°ü ºÎ¹®Àº 2022³â¿¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

±¹°¡º°·Î º¸¸é À¯·´ÀÇ ¿ÏÁ¦ Á¦Á¶ ½ÃÀåÀº ¿µ±¹, µ¶ÀÏ, ÇÁ¶û½º, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ ¹× ±âŸ À¯·´À¸·Î ±¸ºÐµË´Ï´Ù. µ¶ÀÏÀº 2022³â À¯·´ÀÇ ¿ÏÁ¦ Á¦Á¶ ½ÃÀå Á¡À¯À²À» µ¶Á¡Çß½À´Ï´Ù.

Becton Dickinson and Co, Gerresheimer AG, Groninger and Co GmbH, IMA Industria Macchine Automatiche SpA, Maquinaria Industrial Dara SL, Nipro Medical Europe NV, NNE AS, Optima Packaging Group Gmbh, Schott AG, SGD SA, Stevanato Group SpA, Syntegon Technology, West Pharmaceutical Services Inc´Â À¯·´ÀÇ ¿ÏÁ¦ Á¦Á¶ ½ÃÀå¿¡¼­ »ç¾÷À» Àü°³ÇÏ´Â ¼±µµ ±â¾÷ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå À¯·´ÀÇ ¿ÏÁ¦(Fill-Finish) Á¦Á¶ ½ÃÀå »óȲ

Á¦5Àå À¯·´ÀÇ ¿ÏÁ¦(Fill-Finish) Á¦Á¶ ½ÃÀå : ÁÖ¿ä »ê¾÷¿ªÇÐ

Á¦6Àå ¿ÏÁ¦(Fill-Finish) Á¦Á¶ ½ÃÀå : À¯·´ ½ÃÀå ºÐ¼®

Á¦7Àå À¯·´ÀÇ ¿ÏÁ¦(Fill-Finish) Á¦Á¶ ½ÃÀå ºÐ¼® : Á¦Ç°º°

Á¦8Àå À¯·´ÀÇ ¿ÏÁ¦(Fill-Finish) Á¦Á¶ ½ÃÀå ºÐ¼® : ¸ð´Þ¸®Æ¼º°

Á¦9Àå À¯·´ÀÇ ¿ÏÁ¦ Á¦Á¶ ½ÃÀå ºÐ¼® : ÃÖÁ¾ »ç¿ëÀÚº°

Á¦10Àå À¯·´ÀÇ ¿ÏÁ¦ Á¦Á¶ ½ÃÀå : ±¹°¡º° ºÐ¼®

Á¦11Àå ¾÷°è Á¤¼¼

Á¦12Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦13Àå ºÎ·Ï

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Europe fill finish manufacturing market was valued at US$ 2,473.26 million in 2022 and is expected to reach US$ 4,772.50 million by 2030; it is estimated to grow at a CAGR of 8.6% from 2022 to 2030.

Elevating Demand for Biologics Drives Europe Fill Finish Manufacturing Market

Biologics constitute a majority of the top-selling drugs, and they represent one of the fastest-growing pharmaceutical industry segments. Since the launch of recombinant protein-based therapies ~30 years ago, the overall biologics market has grown at an annual rate of more than 12%. Further, over 5,000 biopharmaceutical product candidates are currently under development. Although biopharmaceuticals offer significant profit margins, high development costs and complex production protocols are the key concerns of the sponsors of these pharmacological interventions. As a result, several start-ups and pharmaceutical giants have begun outsourcing different processes of their business operations to contract service providers. Moreover, outsourcing jobs to contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) reduces the requirement of capital investments, provides access to larger production capacities, decreases the time-to-market of products, and lowers risks associated with the commercialization of products.

Fill finish is the final step in the production process, and it is one of the most crucial stages of drug manufacturing. Biologics require special procedures and equipment for fill finish operations to ensure product integrity and safety. Thus, the rise in demand for biologics has resulted in an equivalent need for flexible aseptic fill finish technologies. Pharmaceutical drug manufacturers collaborate with contract service providers to leverage their experience and expertise in the latest fill finish technologies. Fill finish manufacturing services are currently provided by approximately 180 companies for a variety of biologics. They are located in over 350 fill finish factories for these contract manufacturing companies across various geographic regions.

Europe Fill Finish Manufacturing Market Overview

The market players in Germany are adopting organic and inorganic growth strategies for market expansion and growth. For instance, in July 2020, Vetter, the contract development and manufacturing organization (CDMO), headquarters in Ravensburg, Germany, announced that it is investing in additional fill/finish capacity with the purchase of a clinical manufacturing site in Austria.

Similarly, The Siegfried Group signed a cooperation and supply agreement with Biopharmaceutical New Technologies, a German immunotherapy company, for the large-scale filling and packaging of commercial quantities of BNT162b2, an innovative COVID-19 vaccine candidate. Following successful approval, the vaccine developed by BioNTech in cooperation with Pfizer, an American pharmaceutical company, will be filled by Siegfried at its Hameln site from mid-2021 onwards. Also, Rentschler Biotechnologie GmbH, leading contract development and manufacturing organization (CDMO) for biopharmaceuticals located in Germany, and Rentschler Fill Solutions GmbH, an independent specialist for aseptic fill and finish services, announced a strategic partnership to provide new state-of-the-art fill and finish facilities and one-stop solutions for biopharmaceutical products to meet the requirements of Rentschler Biotechnologie's clients.

Europe Fill Finish Manufacturing Market Revenue and Forecast to 2030 (US$ Million)

Europe Fill Finish Manufacturing Market Segmentation

The Europe fill finish manufacturing market is segmented based on product, modality, end user, and country. Based on product, the Europe fill finish manufacturing market is bifurcated into consumables and instruments. The consumables segment held a larger market share in 2022. Furthermore, the consumables is sub segmented into prefilled syringes, glass vial/plastic vials, cartridges, and others.

By modality, the Europe fill finish manufacturing market is segmented into recombinant proteins, monoclonal antibodies, vaccines, cell therapies and biological therapies, gene therapies, and others. The vaccines segment held the largest market share in 2022.

In terms of end user, the Europe fill finish manufacturing market is categorized into contract manufacturing organizations, biopharmaceutical companies, and others. The contract manufacturing organizations segment held the largest market share in 2022.

Based on country, the Europe fill finish manufacturing market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe fill finish manufacturing market share in 2022.

Becton Dickinson and Co, Gerresheimer AG, Groninger and Co GmbH, IMA Industria Macchine Automatiche SpA, Maquinaria Industrial Dara SL, Nipro Medical Europe NV, NNE AS, Optima Packaging Group Gmbh, Schott AG, SGD SA, Stevanato Group SpA, Syntegon Technology GmbH, and West Pharmaceutical Services Inc are some of the leading players operating in the Europe fill finish manufacturing market.

Table Of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Europe Fill Finish Manufacturing Market Landscape

5. Europe Fill Finish Manufacturing Market - Key Industry Dynamics

6. Fill Finish Manufacturing Market - Europe Market Analysis

7. Europe Fill Finish Manufacturing Market Analysis - Product

8. Europe Fill Finish Manufacturing Market Analysis - Modality

9. Europe Fill Finish Manufacturing Market Analysis - End User

10. Europe Fill Finish Manufacturing Market - Country Analysis

11. Industry Landscape

12. Company Profiles

13. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â